fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
Company profile
Ticker
FATE
Exchange
Website
CEO
John Wolchko
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Fate Therapeutics (UK) Ltd. • Tfinity Therapeutics, Inc. • Fate Therapeutics B.V. • Senescea Therapeutics, Inc. ...
FATE stock data
Latest filings (excl ownership)
8-K
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
20 Mar 24
424B5
Prospectus supplement for primary offering
20 Mar 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
26 Feb 24
EFFECT
Notice of effectiveness
28 Nov 23
CORRESP
Correspondence with SEC
21 Nov 23
UPLOAD
Letter from SEC
15 Nov 23
8-K
Entry into a Material Definitive Agreement
8 Nov 23
S-3
Shelf registration
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
Transcripts
FATE
Earnings call transcript
2023 Q4
26 Feb 24
FATE
Earnings call transcript
2023 Q3
8 Nov 23
FATE
Earnings call transcript
2023 Q2
8 Aug 23
FATE
Earnings call transcript
2023 Q1
3 May 23
FATE
Earnings call transcript
2022 Q4
28 Feb 23
FATE
Earnings call transcript
2022 Q3
4 Nov 22
FATE
Earnings call transcript
2022 Q2
4 Aug 22
FATE
Earnings call transcript
2022 Q1
5 May 22
FATE
Earnings call transcript
2021 Q4
1 Mar 22
FATE
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
4
Jeremy Green
25 Mar 24
SC 13D/A
Redmile Group, LLC
25 Mar 24
4
Edward J Dulac III
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
Boxer Capital, LLC
12 Feb 24
SC 13G/A
Capital World Investors
9 Feb 24
4
J Scott Wolchko
2 Feb 24
4
CINDY TAHL
2 Feb 24
4
Edward J Dulac III
2 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 48.51 mm | 48.51 mm | 48.51 mm | 48.51 mm | 48.51 mm | 48.51 mm |
Cash burn (monthly) | 4.49 mm | 4.07 mm | 17.09 mm | 17.24 mm | 12.76 mm | 14.25 mm |
Cash used (since last report) | 26.71 mm | 24.20 mm | 101.69 mm | 102.55 mm | 75.90 mm | 84.78 mm |
Cash remaining | 21.80 mm | 24.31 mm | -53.18 mm | -54.04 mm | -27.39 mm | -36.27 mm |
Runway (months of cash) | 4.9 | 6.0 | -3.1 | -3.1 | -2.1 | -2.5 |
Institutional ownership, Q3 2023
96.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 167 |
Opened positions | 20 |
Closed positions | 39 |
Increased positions | 59 |
Reduced positions | 53 |
13F shares | Current |
---|---|
Total value | 201.61 bn |
Total shares | 95.44 mm |
Total puts | 8.80 k |
Total calls | 900.00 |
Total put/call ratio | 9.8 |
Largest owners | Shares | Value |
---|---|---|
Redmile | 13.12 mm | $27.82 bn |
BLK Blackrock | 12.48 mm | $26.47 bn |
Vanguard | 10.91 mm | $23.13 bn |
BLVGF Bellevue | 4.85 mm | $10.29 bn |
D. E. Shaw & Co. | 4.71 mm | $9.99 bn |
JNJ Johnson & Johnson | 3.38 mm | $7.16 bn |
JPM JPMorgan Chase & Co. | 2.60 mm | $5.50 bn |
FHI Federated Hermes Inc - Ordinary Shares | 2.45 mm | $5.20 bn |
Jacobs Levy Equity Management | 2.39 mm | $5.06 bn |
STT State Street | 2.27 mm | $4.82 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 24 | Redmile | Pre-Funded Warrants to Purchase Common Stock Common Stock | Grant | Acquire A | Yes | No | 5.499 | 3,636,364 | 20.00 mm | 3,893,674 |
4 Mar 24 | Edward J Dulac III | Common Stock | Sell | Dispose S | No | Yes | 7.77 | 2,447 | 19.01 k | 101,479 |
29 Jan 24 | Edward J Dulac III | Common Stock | Sell | Dispose S | No | Yes | 5 | 1,849 | 9.25 k | 103,926 |
9 Jan 24 | Bahram Valamehr | Common Stock | Sell | Dispose S | No | No | 4.38 | 11,271 | 49.37 k | 158,069 |
9 Jan 24 | J Scott Wolchko | Common Stock | Sell | Dispose S | No | No | 4.37 | 14,391 | 62.89 k | 371,248 |
News
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
19 Mar 24
HC Wainwright & Co. Reiterates Neutral on Fate Therapeutics, Maintains $7 Price Target
19 Mar 24
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
27 Feb 24
Barclays Maintains Overweight on Fate Therapeutics, Raises Price Target to $10
27 Feb 24
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
27 Feb 24
Press releases
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
19 Mar 24
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
5 Mar 24
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2 Feb 24